Falciparum malaria

Reading File

Researching falciparum malaria across pathophysiology/clinical features, diagnosis/management, and relevant imaging/microscopy.

search_medical_text

Plasmodium falciparum malaria pathophysiology clinical features complications

Harrison's Principles of Internal Medicine, Twenty First Edition

Page 6341

search_medical_text

falciparum malaria diagnosis treatment management antimalarial drugs

Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV

Page 299

search_medical_image

Plasmodium falciparum blood smear microscopy malaria

Hugging Face pmc clinical VQA raw

Page 0

GradeResponse

Here is a comprehensive overview of Plasmodium falciparum malaria:

Plasmodium falciparum Malaria

Epidemiology

P. falciparum is the most lethal malaria species. It predominates in sub-Saharan Africa, accounting for >80% of malaria infections and ~90% of malarial deaths worldwide. All Plasmodium species are transmitted by the bite of female Anopheles mosquitoes in tropical and subtropical regions. (Harrison's, p. 6341)

Why P. falciparum Is Uniquely Dangerous

Feature	P. falciparum	Other species
Erythrocyte invasion	Any RBC (no restriction)	Only reticulocytes (vivax/ovale)
Parasitemia level	Very high	Lower
Cytoadherence	Yes — adheres to vascular endothelium	Minimal
Drug resistance	Most common	Less frequent
Persistent liver stage	No	P. vivax, P. ovale (hypnozoites)

Pathophysiology

Cytoadherence & sequestration — Infected RBCs express PfEMP1 (P. falciparum erythrocyte membrane protein 1) on their surface, causing them to adhere to capillary and post-capillary venule endothelium. This sequesters parasitized cells in deep vascular beds (brain, lung, kidney, gut), causing microvascular obstruction and organ damage.
Rosetting — Infected RBCs bind uninfected RBCs, further obstructing microcirculation.
High parasitemia — Destruction of RBCs leads to hemolytic anemia, hemoglobinuria, and metabolic acidosis.
Cytokine storm — TNF-α, IL-1, IL-6 drive fever, rigors, and systemic inflammation.

Clinical Features

Uncomplicated malaria:

Paroxysms of fever (often irregular/daily in falciparum, unlike the 48-h tertian cycle)
Chills, rigors, diaphoresis
Headache, myalgia, arthralgia
Nausea, vomiting, abdominal pain
Splenomegaly, mild hepatomegaly
Anemia, thrombocytopenia

Severe/complicated malaria (WHO criteria — any of the following):

Complication	Key Features
Cerebral malaria	Unarousable coma (GCS ≤11), seizures
Severe anemia	Hb <7 g/dL
Respiratory distress	ARDS-like picture
Hypoglycemia	Especially with quinine/quinidine treatment
Renal failure	"Blackwater fever" (hemoglobinuria + AKI)
Circulatory collapse	Algid malaria (septic shock picture)
Abnormal bleeding	DIC
Hyperparasitemia	>5% parasitized RBCs
Jaundice	Hemolytic + hepatic

Diagnosis

Thick and thin Giemsa-stained blood smears — gold standard; thick smear for sensitivity, thin smear for species ID
Characteristic findings on thin smear:
- Multiple ring forms per RBC
- Appliqué (Maurer's clefts) forms
- Banana-shaped (crescentic) gametocytes — pathognomonic for P. falciparum
- No enlarged RBCs (unlike vivax/ovale)
Rapid Diagnostic Tests (RDTs) — detect HRP-2 or pLDH antigens; useful in field settings
PCR — gold standard for species confirmation and drug-resistance genotyping

Giemsa-stained thin blood smear showing P. falciparum with crescentic gametocytes (banana-shaped), characteristic of the species

Giemsa-stained thin blood smear showing P. falciparum gametocytes (banana/crescentic shape) — pathognomonic for this species. Inset also illustrates an insecticide-treated bed net (ITN), a key prevention tool.

Treatment

Treatment depends on disease severity, geographic resistance patterns, age, and pregnancy status. (OI Guidelines, p. 299)

Uncomplicated P. falciparum

Scenario	First-line Options
Chloroquine-susceptible	Chloroquine phosphate OR artemether-lumefantrine OR atovaquone-proguanil OR quinine + doxycycline/clindamycin
Chloroquine-resistant (most of the world)	Artemether-lumefantrine (preferred) OR atovaquone-proguanil OR quinine + doxycycline/tetracycline/clindamycin
Mefloquine	Alternative only

Key principle: Chloroquine should NOT be used in areas with known chloroquine-resistant P. falciparum. Artemisinin-based combination therapies (ACTs) are the WHO-recommended backbone globally.

Severe/Complicated P. falciparum

IV artesunate — WHO/CDC preferred agent for severe malaria (superior to quinine in RCTs)
IV quinidine gluconate + doxycycline OR clindamycin OR tetracycline — alternative where artesunate unavailable
Followed by a complete oral ACT course once patient can tolerate oral therapy
Adjunctive care: correct hypoglycemia (monitor with quinine/quinidine), manage raised ICP in cerebral malaria, renal replacement therapy for AKI, mechanical ventilation for ARDS

Drug Interactions (HIV co-infection)

Quinidine is contraindicated with ritonavir; use with caution alongside atazanavir, darunavir, fosamprenavir
Ritonavir may need to be substituted if IV quinidine is required

Chemoprophylaxis & Prevention

Atovaquone-proguanil, doxycycline, or mefloquine depending on destination and patient factors
Insecticide-treated bed nets (ITNs), indoor residual spraying
DEET-based repellents
Trimethoprim-sulfamethoxazole is NOT recommended for antimalarial prophylaxis
G6PD deficiency must be excluded before primaquine (relevant for P. vivax/ovale radical cure, not falciparum)

Special Populations

Population	Consideration
Pregnancy	High risk of severe disease, fetal loss, LBW; avoid artemisinin in 1st trimester if possible; quinine + clindamycin preferred in 1st trimester
Children	Cerebral malaria and severe anemia disproportionately affect children <5 years
HIV co-infection	Treatment choice unchanged but monitor drug–drug interactions
Travelers	Pre-travel counseling essential; treat as chloroquine-resistant unless confirmed susceptible region

Prognosis

Uncomplicated falciparum malaria treated promptly: good prognosis
Cerebral malaria: 15–20% mortality even with treatment; neurological sequelae in survivors
Overall case fatality rate heavily dependent on access to IV artesunate and ICU-level care

This is a shared conversation. Sign in to Orris to start your own chat.